Home > Boards > US OTC > Delisted > Endologix Inc. (fka ELGXQ)

Reported: $12

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
mlkrborn Member Profile
Followed By 39
Posts 7,816
Boards Moderated 1
Alias Born 01/04/06
160x600 placeholder
mlkrborn   Wednesday, 02/22/12 06:02:01 PM
Re: None
Post # of 66 
Reported: $12
Endologix misses by $0.01, reports revs in-line; guides FY12 EPS below consensus, revs in-line (ELGX) : Reports Q4 (Dec) loss of $0.06 per share, $0.01 worse than the Capital IQ Consensus Estimate of ($0.05); revenues rose 21.9% year/year to $23.4 mln vs the $23.51 mln consensus. Co issues mixed guidance for FY12, sees EPS of ($0.12)-(0.18) vs. ($0.05) Capital IQ Consensus Estimate; sees FY12 revs of $102-107 mln vs. $106.42 mln Capital IQ Consensus Estimate. Co expects quarterly progress towards profitability over the course of the year. Guidance takes into account the planned growth of the direct sales force in Europe, and research & development and clinical/regulatory initiatives, particularly for the Nellix and Ventana devices. Not included in this loss per share guidance are potential adverse litigation outcomes, fair value adjustments associated with the Nellix acquisition, or the effect of other possible business development transactions. The Company expects to be cash flow positive in the second half of 2012 and believes that it has adequate cash resources to fund its operations and growth strategies.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences